19 Pharm of Movement Disorders Flashcards
MOA of bromocriptine
D2 agonist, D1 partial agonist
ADE of bromocriptine
GI (anorexia, N/V), tachycardia,orthostatic hypotension
MOA of pramipexole
D2 selective agonist. Free radical scavenger
ADE of pramipexole
GI (anorexia, N/V), tachycardia,orthostatic hypotension
MOA of ropinirole
D2 selective, metabolized by CYP1A2
ADE of ropinirole
GI (anorexia, N/V), tachycardia,orthostatic hypotension
MOA of amantadine
enhance DA release (antiviral). may also inhibit uptake. interact with NMDA receptors
ADE of amantadine
restlessness, depression agitation, hallucinationss. Overdose = psychosis
MOA of selegiline
MAO-B. inhibits DA metabolism
ADE of selegiline
may potentiate advese effects of L-DOPA
Do not give with meperidine, TCAs or SSRIs
MOA of rasagiline
MAO-B. inhibits DA metabolism. more potent than selegiline
ADE of rasagiline
GI (anorexia, N/V), tachycardia,orthostatic hypotension
MOA of entacapone
COMT. inhibits DA metabolism. Reduces production of 30MD which competes with L-DOPA for transport into BBB and GI.
Strictly has peripheral effects
ADE of entacapone
GI (anorexia, N/V), tachycardia,orthostatic hypotension
MOA of tolcapone
COMT. inhibits DA metab. has both peripheral and central effects. Entacapone is better.